Genedrive MT-RNR1 ID Kit to detect genetic variation and protect hearing in babies: early value appraisal.
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
Here we to examine how subcutaneous diuretic therapy is poised to transform the management of heart failure edema. SQ Innovation announced on April 28, 2026, that its Lasix® ONYU subcutaneous furosemide drug-device combination has achieved CE Marking under the EU Medical Device Regulation and has...
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced Predictive Insights
TikTok Opioid Overdose Forecasting is gaining attention as a powerful new approach to public health surveillance. A new study shows that comments on opioid-related TikTok videos can significantly improve predictions of synthetic opioid deaths, reducing forecasting errors by up to 37% compared wit...
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program for Innovative Techno...
The European Medicines Agency (EMA) has launched a pilot programme to deliver breakthrough medical device access for high-risk technologies that address unmet medical needs. Starting 28 April 2026, the initiative offers enhanced scientific advice and priority access to expert panels for developer...